anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses traditional Chinese medicine mask powder as well as a preparation method and a use method thereof. The traditional Chinese medicine mask powder comprises wormwood, lily, holly, mulberry bark, semen coicis, Chinese angelica, codonopsis pilosula, radix angelicae, an apricot kernel, pearl powder and vitamin C powder. The preparation method comprises the steps of cleaning and drying the traditional Chinese medicines, adding the pearl powder and the vitamin C powder, grinding into powder, screening with a 300-500-mesh screen, uniformly mixing, and carrying out sterilization to prepare the traditional Chinese medicine mask powder. The use method comprises the steps of adding essential oil, vitamin E into the traditional Chinese medicine mask powder, then adding one or more of honey, egg white, acidophilus milk, cucumber juice and sponge gourd juice and water, preparing into paste, applying on skin for 10-15min, and cleaning. The traditional Chinese medicine mask powder adopts natural herbal raw materials, is safe and reliable and has no side effects. The powder has effects of whitening, nourishing and moisturizing skin, improving skin elasticity, removing freckles and the like.
BACKGROUND/AIM: Transient pain enhancement or flare pain, is observed following the administration of immune checkpoint inhibitors (ICIs). However, the detailed mechanism of this phenomenon remains unclear. In this report, we present our experience of documenting the course of flare pain following ICI administration in six cases.
PATIENTS AND METHODS: Six patients with advanced solid tumors received ICI monotherapy between July 2017 and November 2019. Their pain increased within hours of ICI administration despite being stable before ICI administration. We evaluated the changes in the numerical rating scale (NRS) score over 72 h after ICI administration.
RESULTS: Four non-small cell lung cancer patients, one gastric cancer patient, and one renal cell cancer patient were included. Four patients experienced an increase in NRS, as evidenced by scores on two or more scales compared to the day before administration, whereas two patients showed an increase only on one scale. The NRS score decreased to almost the same level as that on the day before administration. Flare pain is observed in the same area as the primary site. Most of the pain was alleviated without the need for rescue analgesics, although one patient experienced a 4-point increase in the NRS scale.
CONCLUSION: Flare pain may occur following ICI administration. Healthcare providers should be aware of these events and provide patients with suitable information and coping techniques.
This study is being done to improve the availability of telehealth urology visits. In this study, investigators will compare the usefulness of data collected by three home devices to understand the amount of urine released from the body, how empty the bladder gets after urinating, and if there is an infection present in the bladder. These will be compared to being at home versus in the doctor's office. Additionally, the study will determine how satisfied patients are when completing a virtual visit for lower urinary tract symptoms (LUTS), related to prostatic enlargement, compared to an in-person visit. The three devices being investigated have not been used in the home setting to make urinary measurements as is typically done in clinic. The goal is to test the effectiveness and accuracy of these devices compared to standard clinical practices and demonstrate the ability of these devices to provide useful information in the home setting. The study involves two cohorts. Cohort 1 are new patients who will be randomized to either telehealth visits or in office visits. If randomized to the telehealth group, the patients will use various devices to perform a standard workup at home. If randomized to the clinic visit, similar tests will be performed in the office. Cohort 2 are existing patients who will use one of the devices at home, but will also complete similar in-office tests in order to compare device accuracy.

Screening will be performed prior to patient's first scheduled visit based on chief complaints of urinary retention, BPH, or LUTS. Patients will be initially identified by study personnel or qualified research coordinator when the patient is identified to have qualifying issues through reviewing medical records of patients. Patient will be contacted by phone by the study personnel. If the patients are interested, the patients will be screened for inclusion criteria.
This drug should be used with great caution, if at all, in patients with glaucoma. 

Glycopyrrolate injection may produce drowsiness or blurred vision. The patient should be cautioned regarding activities requiring mental alertness such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug. 

In addition, in the presence of fever, high environmental temperature and/or during physical exercise, heat prostration can occur with use of anticholinergic agents including glycopyrrolate (due to decreased sweating), particularly in children and the elderly. 

Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with glycopyrrolate injection would be inappropriate and possibly harmful.
Children with cerebral palsy (CP) and those with avascular necosis (AVN) after treatment of developmental hip dysplasia (DDH) are at risk of developing coxa valga. Proximal femur guided growth is a minimally invasive option to correct this deformity. A systematic review of articles that described treatment of coxa valga with proximal femur guided growth (PFGG) and reporting on primary radiographic outcomes, demographic variables, surgical variables and complications. One hundred and seventy-nine hips underwent PFGG (117 with CP and 62 with lateral overgrowth). Average age at surgery was 8.1 years; average follow-up was 52.5 months. Migration percentage improved from 11.2% (p < 0.0001). Neck-shaft angle improved by 11.9° (p < 0.0001). The most common complication was screw growth out of the physis (30% of cases). PFGG can correct coxa valga, improve radiographic parameters, and in children with CP prevent further subluxation. This technique modulates proximal femur growth, induces changes to the acetabulum and can correct valgus deformity. Evidence Level III. (Journal of Surgical Orthopaedic Advances 32(4):049-052, 2024).
The present invention discloses a method for separating and extracting lipo-alkaloids in Radix Aconiti Kusnezoffi class of traditional Mongolian medicine. Namely the Radix Aconiti Kusnezoffi class of traditional Mongolian medicine is executed with ultrasonic extracting with ethanol and then is executed with cold soaking for volatilizing the ethanol and obtaining the extract. The extract is treated by the hydrochloric acid solution and filtered for obtaining the precipitate. Furthermore the precipitate is dissolved into the chloroform. The hydrochloric acid solution is used for extracting repeatedly for several times for volatilizing the chloroform and extracting the coarse lipo-alkaloids. A silica gel column and a cyclohexane-ethanol system are used for executing column chromatography. The pure lipo-alkaloids are separated and extracted with a yield more than 0.22%.
PROBLEM TO BE SOLVED: To obtain the subject polymer having controlled retention in a vein, high contrast effect and improved safety in its injection into a vein and useful as a X-ray contrast medium by including a roentgenopaque molecular structure in the molecule. SOLUTION: This polymer has a roentgenopaque molecular structure, a straight hydrophobic polymer at the center, a hydrophilic polymer bound to the hydrophobic polymer and suppressed intermolecular association. This polymer is preferably a star-type polymer of the formula M-(-A-B-)n  A is a hydrophobic copolymer component having a roentgenopaque molecular structure, e.g. polystyrene or polyvinyl pyridine; B is a hydrophilic copolymer component, e.g. polyethylene oxide or polyvinyl alcohol; M is a focal material bound to A-side of copolymer molecular chains radially extended to (n) directions [(n)>=3] e.g. trimellitic acid}. The roentgenopaque molecular structure is preferably an iodine compound.
PROBLEM TO BE SOLVED: To provide a blood vessel improving agent which contains as an active ingredient an elastin peptide extracted from a bulbus arteriosus of fishes.SOLUTION: A blood vessel improving agent contains as an active ingredient an elastin peptide extracted from a bulbus arteriosus of fishes. The total content of glycine, alanine, valine, and proline per 1000 residues is 650 residues or more. The total content of aspartic acid and asparagine is 10-35 residues. The total content of glutamic acid and glutamine is 20-50 residues. The total content of lysine, histidine, and arginine is 20-50 residues. The total content of desmosine and isodesmosine is 0.3 residues or more. The content of hydroxyproline is 10 residues or less.
The COVID-19 pandemic has been one of the most impactful events in our lifetime, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Multiple SARS-CoV-2 variants were reported globally, and a wide range of symptoms existed. Individuals who contract COVID-19 continue to suffer for a long time, known as long COVID or post-acute sequelae of COVID-19 (PASC). While COVID-19 vaccines were widely deployed, both unvaccinated and vaccinated individuals experienced long-term complications. To date, there are no treatments to eradicate long COVID. We recently conceived a new approach to treat COVID in which a 15-amino-acid synthetic peptide (SPIKENET, SPK) is targeted to the ACE2 receptor binding domain of SARS-CoV-2, which prevents the virus from attaching to the host. We also found that SPK precludes the binding of spike glycoproteins with the receptor carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) of a coronavirus, murine hepatitis virus-1 (MHV-1), and with all SARS-CoV-2 variants. Further, SPK reversed the development of severe inflammation, oxidative stress, tissue edema, and animal death post-MHV-1 infection in mice. SPK also protects against multiple organ damage in acute and long-term post-MHV-1 infection. Our findings collectively suggest a potential therapeutic benefit of SPK for treating COVID-19.
Chronic rhinosinusitis with nasal polyps (CRSwNPs) is a heterogeneous disease characterized by local inflammation of the upper airway and sinus mucosa. T cell-mediated immune responses play irreplaceable roles in the pathogenesis of nasal polyps. CD161+ T cells have been implicated in the pathology of several diseases through cytokine production and cytotoxic activity. However, the immunological characteristics of CD161+ T cells in nasal mucosa are still not well understood, particularly in CRSwNPs. Our research revealed a notable enrichment of CD161+ T cells in nasal tissues compared to peripheral blood, with a significantly more infiltration of CD161+ T cells in CRSwNPs compared to control nasal samples. Phenotypical analysis found that CD161+ T cells predominantly co-expressed tissue-resident memory surface markers CD103, CD69, and CD45RO. CD161+CD103+ T cells demonstrated complicated effector functions, marked by elevated levels of PD-1, CTLA-4, IL-17, and IFN-γ and diminished expression of FoxP3 and CD25. Interestingly, despite CD161+ T cells was more abundant in polyp tissues compared to normal control tissues, and then further categorizing polyp samples into distinct groups based on clinical characteristics, only the recurrent CRSwNP group showed a significant reduction in CD161+CD8+ T cells compared to the primary CRSwNP group. This finding suggested the necessity for further research to comprehensively understand the underlying mechanisms and the broader significance of CD161+ T cells in the advancement and relapse of CRSwNPs.
Polyunsaturated fatty acid ("PUFA") or a pharmacologically acceptable salt or derivative thereof (such as EPA and/or DHA) is used in combination with at least one of an immunosuppressive agent or an antineoplastic agent or a pharmacologically acceptable salt or derivative thereof in the treatment of conditions involving acutely or chronically inadequate immune response by topical application of said active agents to at least a portion of the intestinal mucosa. Specific conditions that may be treated include chronic inflammatory disease (e.g. Chrohn's disease and ulcerative colitis) and tumour disease (e.g. bowel cancer and prostate cancer). One advantage of preferred embodiments of the invention is that bioavailability of immunosuppressive or antineoplastic agents is increased. ® KIPO & WIPO 2007
NEW MATERIAL:The angelic acid unsaturated ester of formula I (R is 5-6C alkenyl). EXAMPLE:3-Methyl-2-butenyl angelate of formula II. USE:A perfume component of a perfumery composition. It has grassy, woody, floral or fruity fragrance, and is useful as a fragrance imparting agent for cosmetic, soap, detergent, shampoo, room perfume, etc., or an agent for imparting or modifying the perfume of food, drink, drug, chewing gum, tooth powder, etc. PROCESS:The compound of formula I can be prepared easily, in high yield, e.g. by the ester exchange reaction of the angelic acid lower alcohol ester of formula III(R' is lower alkyl, especially CH3 or C2H5) with the 5-6C unsaturated alcohol of formula IV in the presence of an ester exchange catalyst such as sodium methoxide at 80-180 deg.C.
PURPOSE:To obtain an aerosol type antiperspirant composition, capable of preventing flocculation of drug powder and excellent in redispersibility and antiperspirant effects with good feeling of use by adding a fine powdery organic polymer having a low specific gravity and substantially spherical shape into the drug powder. CONSTITUTION:The objective substance obtained by blending 0.5-15wt.% drug powder (e.g. aluminum chlorohydroxide) and inorganic assistant powder (e.g. talc) having antiperspirant action with 0.5-15wt.% spherical fine powdery organic polymer (e.g. a crosslinked acrylate polymer) having <=2.5 true specific gravity and 0.1-50mu particle diameter, 99-70wt.% combustible liquefied gas (e.g. dimethyl ether), further, as necessary, blending a stabilizer, oil, germicide, perfume, etc., therewith and preparing a composition.
Conventional methods for measuring carotenoids are HPLC based approaches which are cumbersome, expensive and not readily accessible. Moreover, these methods cannot be applied when only a small amount of biological sample is available from non-invasive procedures such as the collection of material from the surface of skin or from swabs. The present inventors have overcome a number of technical difficulties to successfully raise for the first time antibodies against carotenoids, particularly against carotenes such as lycopene or xanthophylls such as lutein. Hence, the present invention provides such antibodies against carotenoids, as well as assays for carotenoids employing such antibodies. Given the increasing recognition of the importance of carotenoids, the successful provision of such antibodies and assays allows for quicker, cheaper and more accessible measurement of carotenoids, including in the diagnosis and help of subjects with carotenoid deficiency. Moreover, availability of antibodies against carotenoids, naturally occurring molecules, provides an opportunity to create a range of new therapeutic vehicles not only to boost carotenoid transport to cells and tissues but for targeted delivery of pharmaceutical, nutraceutical and other agents.
PROBLEM TO BE SOLVED: To enable to stabilize a solution of a peptide including a specific sequence by adding an organic acid to the solution and regulating the pH. SOLUTION: An organic acid (e.g. tartaric acid, citric acid or acetic acid) is added to a solution of a peptide (e.g. desulfatohirudine or a hirudine variant) changing to succinimide body of formula I or a β-transition material of formula II according to a time passage, and further sucrose and mannitol is added to the organic acid-added solution. An alkali is further added to the obtained solution to regulate the pH of the solution so as to be 5-6.5, and the pH- regulated solution is freeze-dried to stabilize hirudine, etc., useful as an anticoagulant drug. The hirudine-containing freeze-dried pharmaceutical composition excellent in stability is obtained by formulating 5-100mol organic acid, 1-500mol sucrose and 10-1000mol mannitol based on 1mol peptide in the before peptide solution (preferably 0.1-500mg/mL), and freeze drying the formulated solution.
Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and erlotinib hydrochloride PO QD on days 8-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Fluorescent probes are a powerful tool for imaging amyloid β (Aβ) plaques, the hallmark of Alzheimer's disease (AD). Herein, we report the synthesis and comprehensive characterization of 21 novel probes as well as their optical properties and binding affinities to Aβ fibrils. One of these dyes, 1Ae, exhibited several improvements over FDDNP, an established biomarker for Aβ- and Tau-aggregates. First, 1Ae had large Stokes shifts (138-213 nm) in various solvents, thereby reducing self-absorption. With a high quantum yield ratio (φ(dichloromethane/methanol) = 104), 1Ae also ensures minimal background emission in aqueous environments and high sensitivity. In addition, compound 1Ae exhibited low micromolar binding affinity to Aβ fibrils in vitro (Kd = 1.603 µM), while increasing fluorescence emission (106-fold) compared to emission in buffer alone. Importantly, the selective binding of 1Ae to Aβ1-42 fibrils was confirmed by an in cellulo assay, supported by ex vivo fluorescence microscopy of 1Ae on postmortem AD brain sections, allowing unequivocal identification of Aβ plaques. The intermolecular interactions of fluorophores with Aβ were elucidated by docking studies and molecular dynamics simulations. Density functional theory calculations revealed the unique photophysics of these rod-shaped fluorophores, with a twisted intramolecular charge transfer (TICT) excited state. These results provide valuable insights into the future application of such probes as potential diagnostic tools for AD in vitro and ex vivo such as determination of Aβ1-42 in cerebrospinal fluid or blood.
A method and apparatus for validating, correcting and reconciling purchase orders. In one embodiment, each line item of the purchase order is validated to ensure that it corresponds to an item offered by the supplier. Each line item can be compared to known errors and the erroneous part number replaced with a correct part number. Line items can be modified in accordance with a set of rules. The supplier can be notified of an invalid line item in a purchase order and can correct the invalid line item either before or after the purchase order is received by the supplier. Corrections performed by the supplier can be used to add to the set of rules to be used to process succeeding purchase orders. An electronic catalog of the buyer can be updated after buyer review to correct erroneous part numbers and other related information from various sources.
Oral formulations and method of formulating photosensitive agents for oral administration during photodynamic therapy (PDT) and Antimicrobial photodynamic therapy (APDT) treatment are presented. The oral formulated photosensitizers show increased solubility and permeability, thus improving the bioavailability of photosensitizers at the treatment site. An orally administered photosensitizer is suitably formulated for mucosal adhesion and absorption via gastrointestinal mucosal membranes. Oral formulation provided herein use lipids and known proteins as carriers for photosensitizers by oral route. Carriers for encapsulating preselected photosensitizers include conventional liposomes, pegylated liposomes, nanoemulsions, nanocrystrals, nanoparticles, fatty emulsions, lipidic formulations, hydrosols, SMEDDS, Alpha-Feto protein (AFP), and Bovine-Serum-Albumin (BSA), fatty emulsions, hot-melt-extrudates and nanoparticles. The oral formulation, in case of a hydrophobic photosensitizer in the present invention, is stabilized using suitable surfactants/solubilizers thus preventing aggregation of the drug in the stomach and until it is absorbed in the duodenum and the small intestine. Oral formulations can be administered in the form of liquid, capsule, tablet, powder, paste or gel. Formulated drugs can be administered orally as one single dose or in multiple doses before administering PDT. In one embodiment Temoporfin (m-THPC) is used as a photosensitizer in the oral formulations. Temoporfin like many hydrophobic photosensitizers are especially suitable to be administered orally because there is no known enzyme system in the mammalian body which can metabolize Temoporfin or similar photosensitizers. Temoporfin can reach the blood system unchanged and fully active after absorption of the formulation in the gastrointestinal tract.
INTRODUCTION: We report the partial regression of metastatic squamous cell carcinoma (SCC) after reduction of long-term azathioprine therapy while awaiting surgery. The patient was a 69-year-old man with a history of kidney transplantation. Moderately differentiated SCC arising in the anterior neck was initially diagnosed, followed later by poorly differentiated SCC metastases to cervical lymph nodes. Lymph node clearance was performed 28 days after a reduction in azathioprine dosage. The palpable lymph node lesion had noticeably decreased in size at the time of surgery, and subsequent histology only detected 7mm and 0.2mm deposits of poorly differentiated SCC in 2 of 5 level I nodes, and a further 10 reactive nodes from levels II and III. One positive level I and another benign level II/III node, demonstrated necrosis, histiocytic infiltration and fibrosis, interpreted as features of regression. Hence, we investigated the role of immune cells in the partial regression of metastatic SCC after reduction of long-term azathioprine therapy while awaiting surgery.
METHODS: Multispectral immunohistochemistry using custom markers was performed on regions of interest of excised cervical lymph nodes, encompassing the entire SCC deposit and the surrounding adjacent stroma to quantify to number and types of immune cells present.
RESULTS: Multispectral immunohistochemistry revealed the heavy infiltration of activated T cells in the tumour, as well as PD-L1+ antigen-presenting cells in the surrounding adjacent stroma, suggesting an immunologically mediated partial regression.
DISCUSSION: We hypothesize that this reaction was triggered by azathioprine dose reduction. Dose modification of long-term immunosuppressive medications in patients with a transplantation history who later develop SCCs warrants further investigation.
The present invention relates to Chen series medicines for treating headache, which belongs to a traditional Chinese medicine prescription. The series medicines use the therapy with syndrome differentiation theory of the Chinese medicine as guide and minutely divide the cause and the quality of headache into eight kinds, which is to say, headache is caused by eight factors (except for foreign body in brain). Because thrombus headache needs further study, the medicine for treating thrombus headache is not in the application. The series medicines are characterized in that the prescription is special for one disease; each prescription is only suitable for headache with one disease symptom. Thus, the administration of the series medicines needs the guide of doctors by heteropathy. The present invention aims to solve the technical problem that the series medicines have a pure Chinese medicinal formula, and the decoction has inconvenient administration; thus, the inventor suggests that the series medicines are made into granules. The problem of the manufacturing process of the granules needs solving.